Selecting SNPs for the array included one or more the following:
1. There is a PharmGKB Clinical Annotation written between the SNP and a drug response, usually with high levels of evidence.
2. It is a functional SNP within a VIP
3. It is a known tag SNPs for an important PGx haplotype
4. It is a SNP of interest to the research groups
252 PGx SNPs (listed in the Supplementary Information) + 2 sex markers + 2 SNPs for quality control
Details of the genotyping array technology, validation, costs and turnaround times are outlined. Also discussed in the article are the current potential barriers to clinical implementation of pharmacogenetics, and how a preemptive genotyping approach can overcome some of these.
Implementing Personalized Medicine: Development of a Cost-Effective Customized Pharmacogenetics Genotyping Array
J A Johnson, B M Burkley, T Y Langaee, M J Clare-Salzler, T E Klein and R B Altman. Clinical Pharmacology & Therapeutics (2012); advance online publication 22 August 2012. doi:10.1038/clpt.2012.125